FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a biomedical cell product with specific antitumor activity, represented by two cell populations: anti-HER2 CAR-T-NK and CAR-γδT-OIL, whose effectiveness is accompanied by simultaneous activation of innate and adoptive immune responses, intended for the treatment of patients with solid tumors expressing the epidermal growth factor receptor (HER2).
EFFECT: product obtaining from autologous mononuclear lymphocytes activated with a human recombinant cytokine preparation and subjected to genetic modification in order to express anti-HER2 CAR.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| GENETICALLY MODIFIED GAMMA DELTA T CELLS | 2015 |
|
RU2756247C2 |
| CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | 2015 |
|
RU2670147C1 |
| BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
